Zoetis (NYSE:ZTS) Price Target Cut to $200.00 by Analysts at JPMorgan Chase & Co.

Zoetis (NYSE:ZTS) had its price objective cut by JPMorgan Chase & Co. from $230.00 to $200.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms have also recently weighed in on ZTS. Stifel Nicolaus set a $140.00 price target on Zoetis in a report on Tuesday. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. UBS Group lowered their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $191.00.

Zoetis Stock Down 3.2%

ZTS opened at $120.47 on Wednesday. The business has a 50 day moving average price of $145.63 and a two-hundred day moving average price of $153.01. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market cap of $53.39 billion, a PE ratio of 20.73, a P/E/G ratio of 2.31 and a beta of 0.90. Zoetis has a 52 week low of $119.07 and a 52 week high of $181.85.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts anticipate that Zoetis will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Institutional Investors Weigh In On Zoetis

A number of hedge funds have recently made changes to their positions in the business. Norges Bank bought a new stake in Zoetis in the second quarter valued at about $809,491,000. Nuveen LLC bought a new stake in Zoetis during the first quarter worth about $616,375,000. Diamond Hill Capital Management Inc. bought a new stake in Zoetis during the third quarter worth about $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Zoetis by 113.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after purchasing an additional 1,782,110 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.